SWPIF - Sawai Pharmaceutical Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD

Sawai Pharmaceutical Co., Ltd.

5-2-30, Miyahara
Osaka 532-0003
81 6 6105 5711

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Mitsuo SawaiPres & Representative DirectorN/AN/AN/A
Mr. Kazuhiko SueyoshiManaging Exec. Officer, Director of Fin., GM of Admin. Headquarters & DirectorN/AN/AN/A
Mr. Toru TerashimaSr. Exec. Officer, VP of Reliability Assurance Div., Gen. Marketing Compliance Officer & DirectorN/AN/AN/A
Mr. Akira HamadaSr. Exec. Officer & GM of HR DepartmentN/AN/AN/A
Mr. Kenzo SawaiSr. Managing Exec. Officer, GM of Strategic Planning Department & DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sawai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products. It offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. The company serves hospitals, general practitioners, and dispensing pharmacies. It has operations in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.

Corporate Governance

Sawai Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of December 5, 2019 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.